1997-50-8 Usage
Uses
Used in Pharmaceutical Industry:
5-FLUORO-8-QUINOLINESULFONYL CHLORIDE is used as a clastogenic compound for its ability to induce chromosomal breakage and rearrangements in cells. This property makes it a valuable tool in the study of genetic mutations and the development of new drugs targeting cancer cells.
Used in Enzyme Inhibition:
5-FLUORO-8-QUINOLINESULFONYL CHLORIDE is used as an inhibitor of CYP enzymes due to its interaction with the quinoline moiety. CYP enzymes are involved in the metabolism of various drugs and xenobiotics, and their inhibition can be useful in the development of drugs with reduced side effects and improved efficacy.
Used in Antibacterial Applications:
5-FLUORO-8-QUINOLINESULFONYL CHLORIDE is used as an antibacterial agent in the medical and pharmaceutical industries. The quinoline moiety in its structure contributes to its ability to inhibit bacterial growth, making it a potential candidate for the development of new antibiotics to combat drug-resistant bacteria.
Check Digit Verification of cas no
The CAS Registry Mumber 1997-50-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,9,9 and 7 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1997-50:
(6*1)+(5*9)+(4*9)+(3*7)+(2*5)+(1*0)=118
118 % 10 = 8
So 1997-50-8 is a valid CAS Registry Number.
InChI:InChI=1/C9H5ClFNO2S/c10-15(13,14)8-4-3-7(11)6-2-1-5-12-9(6)8/h1-5H
1997-50-8Relevant academic research and scientific papers
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Page/Page column 179; 180, (2014/09/29)
Compounds of general formula (I) and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Paragraph 0740; 0741, (2014/09/30)
Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Page/Page column 192; 193, (2014/09/29)
Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
